COMPANY PROFILE

Alys Pharmaceuticals

Explore full profile

An Innovation Leader in Immuno-Dermatology

Boston, United StatesFounded 2024Biotech & Life Sciences

Valuation $500M–1B Last recorded · 2024

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Alys Pharmaceuticals

Alys Pharmaceuticals, Inc. is a company focused on immuno dermatology, aiming to redefine the treatment landscape with transformative solutions. The company operates in the pharmaceutical and biotechnology market, specifically targeting dermatological conditions through its innovative programs and platforms. Alys Pharmaceuticals serves patients with dermatological needs, leveraging its robust R&D pipeline enabled by multiple platform technologies. The business model revolves around developing and advancing its pipeline of dermatological treatments, funded by significant investments such as the recent $100 million financing from Medicxi. The company generates revenue through the development and commercialization of its dermatological therapies, potentially partnering with other pharmaceutical companies for distribution and further development.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2024
Headquarters: Boston, United States
Employees: 10
Open positions: None listed
Dealroom signal: 86.5/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Dermatology, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Investment activity: 6 companies
Capital deployed: —
Preferred round: Unknown
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

1 recorded event

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SEEDOther financing	Feb 2024	$100M	$400M	Medicxi	↗

Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Alys Pharmaceuticals website traffic

Latest recorded traffic for Alys Pharmaceuticals is 2.4K monthly website visits, down 35.1% over the last three months. Alys Pharmaceuticals's team grew 25% over the past year.

Latest monthly visits2.4K 3-month web change-35.1% 1-year team growth+25%

Monthly website visitsFeb 2024–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
CICorium InternationalEngages in the development of advanced transdermal drug delivery technologies and products	Menlo Park, United States	Acquired	253	$185M	$400M
IPIlya PharmaIlya Pharma develops immune-cell therapies. The company's biological medicine uses lactic acid bacteria as vectors to deliver biological drugs on-site to skin wounds or the GI tract	Uppsala kommun, Sweden	Operational
LHLegacy HealthcareBiopharma developing innovative botanical drugs in supportive oncology care and dermatology	Epalinges, Switzerland	Operational
MEMedherantNovel transdermal patch for controlled drug delivery	Coventry, United Kingdom	Operational
ARArrayPatchPainless, dissolvable microneedle patch for dermatological treatments	Cork, Ireland	Operational
LPLX Bio PharmaceuticalsBiotechnology pharmaceutical company focused on developing antibody and bacteriophage therapies for unmet medical needs	Lisbon, Portugal	Operational
MBMatriSys BioscienceClinical stage specialty biopharmaceutical company	San Diego, United States	Operational
DEDermiraDevelopment-stage biotech company focused on developing and commercializing innovative new therapies in dermatology	Redwood City, United States	Acquired